{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:52:22Z","timestamp":1791139942737,"version":"4.1.0"},"reference-count":53,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,12,29]],"date-time":"2011-12-29T00:00:00Z","timestamp":1325116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Rheumatoid arthritis (RA) is associated with an increased risk of ischemic heart disease, in both early and established RA. Data on the risk of ischemic heart disease in relation to therapy with tumor necrosis factor (TNF) antagonists (anti\u2010TNF) are conflicting in patients with established RA and essentially lacking in those with early RA. In established RA, the risk of myocardial infarction has been linked to the response to anti\u2010TNF therapies. The aim of this study was to determine the risk of acute coronary syndromes (ACS) in patients with early RA in relation to treatment with, and response to, anti\u2010TNF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cohort consisting of patients in whom RA was diagnosed between 1999 and 2007 was identified from the Swedish Rheumatology Register (n = 6,000), from which information on disease activity and pharmacologic treatments was extracted. In a cohort study, the risk of first occurrence of an ACS was compared between patients treated with anti\u2010TNF and those without exposure to anti\u2010TNF, using hazard ratios (HRs). In a nested case\u2013control study, the relationship between response to anti\u2010TNF according to the European League Against Rheumatism (EULAR) response criteria and the risk of ACS was investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the cohort study, treatment with anti\u2010TNF was not related to any statistically significant alteration in the risk of ACS (HR 0.80, 95% confidence interval [95% CI] 0.52\u20131.24). In the nested case\u2013control study, a good or moderate EULAR treatment response at 3 months and at 6 months was not associated with a risk of ACS (odds ratio [OR] 1.7, 95% CI 0.5\u20135.1 and OR 1.5, 95% CI 0.3\u20136.9, respectively), when adjusted for disease activity before treatment start.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this study of patients treated with anti\u2010TNF within the first years of RA, neither treatment with, nor response to, anti\u2010TNF therapy could be linked to any statistically significant decrease in the risk of ACS.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.30654","type":"journal-article","created":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T03:44:46Z","timestamp":1314848686000},"page":"42-52","source":"Crossref","is-referenced-by-count":61,"title":["Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis"],"prefix":"10.1002","volume":"64","author":[{"given":"Lotta","family":"Ljung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia F.","family":"Simard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Jacobsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solbritt","family":"Rantap\u00e4\u00e4\u2010Dahlqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Askling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Anti\u2010Rheumatic Therapy in Sweden (ARTIS) Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12,29]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"2597","article-title":"Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis","volume":"28","author":"Wallberg\u2010Jonsson S","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-4-200602210-00006"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000054612.26458.B2"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.018101"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23650"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370408"},{"key":"e_1_2_7_9_2","first-page":"445","article-title":"Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden","volume":"24","author":"Wallberg\u2010Jonsson S","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel253"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2323"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2010.02260.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20853"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24855"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21397"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000037521.71373.44"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.026534"},{"key":"e_1_2_7_18_2","first-page":"309","article-title":"Short\u2010term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab","volume":"24","author":"Gonzalez\u2010Juanatey C","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.601641"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740500474578"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092171"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740802363768"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.063867"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22094"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22255"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22809"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23811"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.067660"},{"key":"e_1_2_7_29_2","first-page":"1213","article-title":"Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis","volume":"32","author":"Jacobsson LT","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.129916"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2383"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.130914"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.045872"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2000.2305"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390105"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043430"},{"key":"e_1_2_7_40_2","first-page":"2562","article-title":"Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset","volume":"26","author":"Wallberg\u2010Jonsson S","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.052506"},{"key":"e_1_2_7_42_2","first-page":"S620","article-title":"Decreased expression of the endothelial cell activation marker HLA\u2010DQ in skeletal muscle after three months of adalimumab treatment in patients with rheumatoid arthritis","volume":"60","author":"Bergstrom U","year":"2009","journal-title":"Arthritis Rheum"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21707"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem089"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-0935-2"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.846105"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc3401.093154"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000109642.27985.FA"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000057810.48709.F6"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27349"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27758"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08213-2"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740410010308"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2045"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.30654","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.30654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T18:55:36Z","timestamp":1696964136000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.30654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,29]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1002\/art.30654"],"URL":"https:\/\/doi.org\/10.1002\/art.30654","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,29]]}}}